AlphAIAlphAI — Financial news for AI agents
prnewswire.comOCT 292 min read$CODX

Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast

Co-Diagnostics (CODX) will release Q3 2026 earnings on Nov 12, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET. Management, including CEO Dwight Egan, will discuss results. The company develops molecular diagnostic tests and has a proprietary platform for at-home and point-of-care testing, pending regulatory approval.

Original reporting
prnewswire.com
Published Oct 29, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast — source image
Source · prnewswire.com
Decision brief

The 30-second read

$CODXNeutralMed
01

Why it matters

The main tradable element is the fixed earnings timing, which can affect options pricing, liquidity, and positioning into the after-close release.

02

Market read

A scheduled earnings release date is a calendar catalyst, but the article does not include results, guidance, or other new fundamentals.

03

What to watch

Traders may still need to monitor whether the company files an earnings release and any supplemental investor presentation on the same day, which can shift expectations beyond the scheduled call time.

Relevance 5/10Novelty 6/10Timing: ahead of the Nov. 12 after-close Q3 2026 earnings release

Background

The company is a molecular diagnostics developer using a patented platform for nucleic-acid based tests, and it is scheduling its Q3 2026 results and analyst call.

Company-level read

Ticker impact

$CODXNeutralHigh confidence
Context

Co-Diagnostics (CODX) announced it will release Q3 2026 financial results on Nov. 12, 2026 after the close, with a 4:30 p.m. ET webcast.

Expected impact

Likely modest pre-earnings positioning and higher implied volatility into the Nov. 12 after-close earnings release.

Evidence & confidence

The article contains only the scheduled earnings release date and webcast time, with no guidance, numbers, or other new fundamentals.

Market effects

Sector

Adds a near-term catalyst for the molecular diagnostics space, but provides no sector-wide data or read-across.

Regional

No direct regional market linkage beyond US small/mid-cap biotech-style earnings calendar effects.

Global

Limited, as the disclosure is company-specific and US-timed.

Counterpoint

What could challenge this read

Because the release date is a routine scheduling update with no new financial content, price impact may be limited until the actual earnings materials are filed.

Key entities

  • company
    Co-Diagnostics, Inc.

    Molecular diagnostics company scheduling its Q3 2026 earnings release and webcast.

  • person
    Dwight Egan

    Chief Executive Officer participating in the earnings call.

  • person
    Daniel Bohrer

    Executive Vice President of Finance and Accounting participating in the earnings call.

Read at source← All news

Related articles

OCT 27
$CODXMed

CoSara submits tuberculosis test for India regulatory review

Co-Diagnostics' India joint venture, CoSara, submitted its tuberculosis test for regulatory review in India, reporting 97.3% sensitivity and 96.0% specificity. The test, using Co-Diagnostics' technology, aims for approval by Q4 2026 to begin sales in India and South Asia. India has the highest tuberculosis burden globally, according to the WHO.

investing.com2 min
OCT 27
$CODXMedAI 8/10

Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India

Co-Diagnostics' joint venture CoSara Diagnostics completed a clinical study for its tuberculosis test, reporting 97.3% sensitivity and 96.0% specificity. The test was submitted to India's CDSCO for regulatory clearance, with a commercial launch anticipated before year-end 2026. The company has also deployed mobile and cloud infrastructure in India to support the launch.

prnewswire.com2 min
AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.

prnewswire.com6 min
AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-

SEC EDGAR 8-K6 min
AUG 13
$CODXMed

Co-Diagnostics submits flu/RSV test after study of more than 1,400 patients

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.

stocktitan.net6 min